Shares of Galectin Therapeutics Inc (NASDAQ:GALT) rose 7.3% during mid-day trading on Wednesday . The company traded as high as $5.26 and last traded at $4.81. Approximately 248,243 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 727,796 shares. The stock had previously closed at $5.19.
GALT has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on Galectin Therapeutics from $3.50 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, November 28th. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Thursday, November 30th. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Roth Capital cut their target price on Galectin Therapeutics from $10.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, December 7th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $5.55.
The stock has a market cap of $174.27, a P/E ratio of -9.44 and a beta of 2.67.
In other Galectin Therapeutics news, Director James C. Czirr sold 205,144 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $5.45, for a total value of $1,118,034.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Fund L.P. 10X sold 244,444 shares of the business’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $5.43, for a total transaction of $1,327,330.92. The disclosure for this sale can be found here. Insiders own 38.80% of the company’s stock.
Large investors have recently bought and sold shares of the business. Advisor Group Inc. grew its stake in shares of Galectin Therapeutics by 7.4% in the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock worth $1,112,000 after acquiring an additional 35,850 shares in the last quarter. Wedbush Securities Inc. acquired a new position in shares of Galectin Therapeutics in the fourth quarter worth $102,000. Vanguard Group Inc. grew its stake in shares of Galectin Therapeutics by 18.2% in the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after acquiring an additional 134,165 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after acquiring an additional 3,176 shares in the last quarter. Institutional investors and hedge funds own 10.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/03/14/galectin-therapeutics-galt-stock-price-up-7-3.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.